Skip to main content

Advertisement

Springer Nature Link
Log in

Infections associated with ruxolitinib: study in the French Pharmacovigilance database

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yang LPH, Keating KM (2012) Ruxolitinib: In the Treatment of Myelofibrosis. Drugs 72 (16):2117–2127

  2. Saeed I, McLornan D, Harrison CN (2017) Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev Hematol 10(7):617–625

  3. Abidi MZ, Haque J, Varma P and al (2016) Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol Article ID 2389038

  4. Malkan UY, Haznedaroglu IC (2017) A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment (case report). Int J Clin Exp Med 10(4):7304–7307

    Google Scholar 

  5. Pálmason R, Lindén O, Richter J (2015) EBV driven lymphoproliferative disorder associated with ruxolitinib (case-report). BMC Hematol 15:10

  6. Cen CC, Chen YY, Huang CE (2016) Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol 95:361–362

  7. Kusano Y, Terui Y, Ueda K and al (2016) Klebsiella pneumoniae primary liver abscess associated withruxolitinib Ann Hematol 95:1561–1562

  8. Shen CH, Hwang CE, Chen YY and al (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93:1075–1076

  9. Manduzio P (2017) Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. Ther Clin Risk Manag 13:169–177

  10. Schönberg K, Rudolph J, Vonnahme M and al (2015) JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res 75(11):2187–2199

Download references

Author information

Authors and Affiliations

  1. French Regional Pharmacovigilance Center, Fernand-Widal Hospital - APHP, 200, rue du faubourg SaintDenis, 75475, Paris, France

    Pinel Sylvine, Sternjacob Thomas & Eftekhari Pirayeh

Authors
  1. Pinel Sylvine
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Sternjacob Thomas
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Eftekhari Pirayeh
    View author publications

    You can also search for this author inPubMed Google Scholar

Consortia

The French Network of Regional Pharmacovigilance Centers

Corresponding author

Correspondence to Pinel Sylvine.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sylvine, P., Thomas, S., Pirayeh, E. et al. Infections associated with ruxolitinib: study in the French Pharmacovigilance database. Ann Hematol 97, 913–914 (2018). https://doi.org/10.1007/s00277-018-3242-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3242-8